公开(公告)号：US11746100B2

公开(公告)日：2023-09-05

申请号：US17242731

申请日：2021-04-28

Applicant: GLOBAL BLOOD THERAPEUTICS, INC.

Inventor： Qing Xu ,  Carsten Alt ,  Zhe Li ,  Shahul Nilar ,  Peter Michael Rademacher ,  Calvin Wesley Yee

IPC: C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D491/056 ,  C07D498/08

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D413/04 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D491/056 ,  C07D498/08

Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I or I′ and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

公开(公告)号：US20230159553A1

公开(公告)日：2023-05-25

申请号：US17921905

申请日：2021-04-28

Applicant: Global Blood Therapeutics, Inc

Inventor： Qing Xu ,  Zhe Li ,  Shahul Nilar

IPC: C07D495/04 ,  C07D519/00

CPC classification number: C07D495/04 ,  C07D519/00

Abstract: The subject matter described herein is directed to ferroportin inhibitor compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

公开(公告)号：US11548880B2

公开(公告)日：2023-01-10

申请号：US16865625

申请日：2020-05-04

Applicant: Global Blood Therapeutics, Inc.

Inventor： Zhe Li

IPC: C07D413/06 ,  A61K31/5377 ,  A61K31/541 ,  C07D417/06 ,  C07D401/06 ,  C07D211/22 ,  C07D403/06 ,  C07D265/30 ,  A61P7/06

Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

公开(公告)号：US11530191B2

公开(公告)日：2022-12-20

申请号：US17026690

申请日：2020-09-21

Applicant: Global Blood Therapeutics, Inc.

Inventor： Brian W. Metcalf ,  Zhe Li ,  Qing Xu ,  Stephen L. Gwaltney, II ,  Jason R. Harris ,  Calvin W. Yee

IPC: C07D401/04 ,  C07D213/30 ,  A61K31/445 ,  A61K31/5375 ,  C07D401/14 ,  C07D405/14 ,  C07D401/12 ,  C07D471/04 ,  C07D257/04 ,  C07D487/04 ,  C07D231/56 ,  C07D211/62 ,  C07D213/64 ,  C07C65/30 ,  C07F7/08 ,  A61K8/49 ,  C07D211/70 ,  C07D213/69 ,  C07D227/08 ,  C07D405/04

Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

公开(公告)号：US20220395492A1

公开(公告)日：2022-12-15

申请号：US17885238

申请日：2022-08-10

Applicant: Global Blood Therapeutics, Inc.

Inventor： Zhe Li ,  Stephan D. Parent ,  Travis Houston

IPC: A61K31/4439 ,  C07D401/04 ,  A61P11/00 ,  A61P25/28 ,  A61P35/00 ,  A61P1/04

Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

公开(公告)号：US11452720B2

公开(公告)日：2022-09-27

申请号：US16923498

申请日：2020-07-08

Applicant: Global Blood Therapeutics, Inc.

Inventor： Zhe Li ,  Stephan D. Parent ,  Travis Houston

IPC: A61K31/4439 ,  C07D401/04 ,  A61P11/00 ,  A61P25/28 ,  A61P35/00 ,  A61P1/04

Abstract: Disclosed are crystalline free base ansolvate forms of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1), such as the free base Form I, Form II and Material N. Also disclosed are crystalline free base solvates of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (or Compound 1).

公开(公告)号：US20220267337A1

公开(公告)日：2022-08-25

申请号：US17665942

申请日：2022-02-07

Applicant: Global Blood Therapeutics, Inc.

Inventor： Lina Q. Setti ,  Shahul Nilar ,  Zhe Li ,  Ming Yu ,  Manuel Zancanella

IPC: C07D487/04

Abstract: The subject matter described herein is directed to pyruvate kinase activating compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds and methods of administering the compounds for the treatment of diseases associated with PKR and/or PKM2, such as pyruvate kinase deficiency, sickle cell disease, and beta-thalassemia.

公开(公告)号：US20210284623A1

公开(公告)日：2021-09-16

申请号：US17337895

申请日：2021-06-03

Applicant: Global Blood Therapeutics, Inc.

Inventor： Zhe Li ,  Nathan Guz ,  Yiyang Shao ,  Julieana Cocuz ,  Markus Frieser ,  George Petros Yiannikouros ,  Liang Liao

IPC: C07D401/04 ,  C07C45/65 ,  C07C47/575

Abstract: Disclosed herein are processes for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde (also referred to herein as Compound (I)) and intermediates used in such processes. Compound (I) binds to hemoglobin and increases its oxygen affinity and hence can be useful for the treatment of diseases such as sickle cell disease.

公开(公告)号：US11014884B2

公开(公告)日：2021-05-25

申请号：US16588753

申请日：2019-09-30

Applicant: Global Blood Therapeutics, Inc.

Inventor： Brian W. Metcalf ,  Zhe Li ,  Qing Xu ,  Kobina N. Dufu ,  James Partridge ,  Hing Sham ,  Ming Yu

IPC: A61K31/444 ,  A61K31/443 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/55 ,  A61K31/5375 ,  A61K31/54 ,  A61K31/44 ,  C07D211/32 ,  A61P7/00 ,  C07D207/12 ,  C07D213/50 ,  C07D223/04 ,  C07D295/104 ,  C07D307/48 ,  C07D401/04 ,  C07D405/04 ,  C07D417/04

Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

公开(公告)号：US20190300477A1

公开(公告)日：2019-10-03

申请号：US16446331

申请日：2019-06-19

Applicant: Global Blood Therapeutics, Inc.

Inventor： Qing Xu ,  Zhe Li

IPC: C07D207/08 ,  C07D401/06 ,  C07D335/02 ,  C07D401/12 ,  C07D211/16 ,  C07C271/16 ,  C07D207/34 ,  C07D211/22 ,  C07D211/60 ,  C07D211/78 ,  C07D213/81 ,  C07D241/04 ,  C07D265/30 ,  C07D279/12 ,  C07D309/08 ,  C07D309/28 ,  C07D333/38 ,  C07D207/48 ,  C07D403/06

Abstract: Provided herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.